Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 1529791

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1529791

Anti-venom Market Size, Share & Trends Analysis Report By Species (Snake, Scorpion), By Type (Polyvalent, Monovalent), By Mode Of Action (Cytotoxic, Neurotoxic), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Anti-venom Market Size & Trends

The global anti-venom market size was estimated at USD 1.18 billion in 2023 and is expected to grow at a CAGR of 8.11% from 2024 to 2030. This growth is attributed to the rising prevalence of venom bites/stings, increasing awareness of anti-venom treatments, growing research initiatives to develop effective treatments, and growing government initiatives to spread. According to the World Health Organization (WHO), approximately 5.4 million people get bitten by snakes each year. Moreover, around 81 410 to 137 880 mortalities occur globally each year as a result of snake bites.

Similarly, several venomous species, such as spiders, scorpions, and others, also significantly contribute to the increasing demand for anti-venom treatments. Bites from these venomous species often lead to various serious conditions and acute medical emergencies such as severe paralysis, which may prevent breathing, lead to bleeding disorders, and may even cause irreversible kidney failure. The increasing awareness about these effects of venom bites and the need for their treatment are expected to fuel the market growth over the forecast period. The countries and regions with weaker health systems and resources experience an increased burden of these conditions caused by venom bites, highlighting the importance of these treatments.

Various research institutes, universities, and healthcare companies are taking initiatives to enhance their R&D on anti-venom for the development of advanced solutions with better results and outcomes. For instance, in October 2022, Monash University Malaysia and Agilent Technologies Inc. signed a MoU for building an integrated biology center in Malaysia. This center is anticipated to help the institutions improve their scientific knowledge to develop better anti-venom & other applied biology research. Similarly, in March 2024, the Institute for Primate Research Kenya announced that it is ready to introduce the first-ever anti-venom produced in any African country. Such research initiatives taken by various institutions are expected to lead to the development of advanced treatments and drive market growth.

Similarly, several governments globally are trying to increase awareness about venomous species and the effects of their bites, which is further anticipated to contribute to market growth. For instance, in MAR 2024, the Union Health Ministry of the Government of India (GOI) launched the National Action Plan for Prevention and Control of Snakebite Envenoming (NAP-SE) in India. A snakebite helpline no was also launched at the event to ensure better access to medical care for the individuals or communities affected by snakebites in five different states of the country. Such increasing government initiatives to increase medical care access for venom bite victims are anticipated to fuel the anti-venom market growth over the forecast period.

Global Anti-venom Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global anti-venom market report based on species, type, mode of action, end-use, and region:

  • Species Outlook (Revenue, USD Million, 2018 - 2030)
  • Snake
  • Common Cobra
  • Common Krait
  • Russell Viper
  • Others
  • Scorpion
  • Spider
  • Other Species
  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Polyvalent
  • Monovalent
  • Mode Of Action Outlook (Revenue, USD Million, 2018 - 2030)
  • Cytotoxic
  • Neurotoxic
  • Haemotoxic
  • Cardiotoxic
  • Myotoxic
  • Others
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Regional Outlook (Revenue in USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Show more
Product Code: GVR-4-68040-357-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Species
    • 1.2.2. Type
    • 1.2.3. Mode of Action
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Species outlook
    • 2.2.2. Type outlook
    • 2.2.3. Mode of Action outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anti-Venom Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidents of venom-bites
      • 3.2.1.2. Increasing R&D initiatives
      • 3.2.1.3. Increasing awareness about importance of anti-venom
      • 3.2.1.4. Rising government initiatives
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited access to the treatments
  • 3.3. Anti-Venom Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.2. PESTEL Analysis

Chapter 4. Anti-Venom Market: Species Estimates & Trend Analysis

  • 4.1. Species Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Anti-Venom Market by Species Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Snakes
      • 4.4.1.1. Snakes market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Common cobra
      • 4.4.1.2.1. Common cobra market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Common krait
      • 4.4.1.3.1. Common krait market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Rusell viper
      • 4.4.1.4.1. Rusell viper market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
      • 4.4.1.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Scorpion
      • 4.4.2.1. Scorpion market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Spider
      • 4.4.3.1. Spider market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Other species
      • 4.4.4.1. Other species market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anti-Venom Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Anti-Venom Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Polyvalent
      • 5.4.1.1. Polyvalent market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Monovalent
      • 5.4.2.1. Monovalent market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anti-Venom Market: Mode of Action Estimates & Trend Analysis

  • 6.1. Mode of action Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Anti-Venom Market by Mode of Action Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Cytotoxic
      • 6.4.1.1. Cytotoxic market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Neurotoxic
      • 6.4.2.1. Neurotoxic market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Haemotoxic
      • 6.4.3.1. Haemotoxic market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Cardiotoxic
      • 6.4.4.1. Cardiotoxic market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Myotoxic
      • 6.4.5.1. Myotoxic market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Anti-Venom Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Anti-Venom Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Hospitals
      • 7.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Clinics
      • 7.4.2.1. Clinics market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Ambulatory surgical centers
      • 7.4.3.1. Ambulatory surgical centers market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Others
      • 7.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Anti-Venom Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. North America
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ Reimbursement
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ Reimbursement
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ Reimbursement
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ Reimbursement
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Denmark
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ Reimbursement
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.9. Norway
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ Reimbursement
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ Reimbursement
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ Reimbursement
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ Reimbursement
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ Reimbursement
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework/ Reimbursement
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ Reimbursement
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ Reimbursement
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ Reimbursement
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ Reimbursement
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. Bharat Serums and Vaccines Limited (BSV)
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Others benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Boehringer Ingelheim International GmbH
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Others benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Boston Scientific Corporation
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Others benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. CSL Limited
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Others benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Haffkine Bio-Pharmaceutical Corporation Limited
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Others benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Incepta Pharmaceuticals Limited
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Others benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Merck & Co., Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Others benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Pfizer, Inc.
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Others benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. MicroPharm Limited
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Others benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Rare Disease Therapeutics Inc.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Others benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. South African Vaccine Producers (Pty) Ltd.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Others benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Medtoxin Venom Laboratories
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Others benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. Instittue of Immunology
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Others benchmarking
      • 9.3.16.4. Strategic initiatives
    • 9.3.17. Alomone Labs, Ltd.
      • 9.3.17.1. Company overview
      • 9.3.17.2. Financial performance
      • 9.3.17.3. Others benchmarking
      • 9.3.17.4. Strategic initiatives
    • 9.3.18. Sigma Aldrich
      • 9.3.18.1. Company overview
      • 9.3.18.2. Financial performance
      • 9.3.18.3. Others benchmarking
      • 9.3.18.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-357-6

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America anti-venom market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 4 North America anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 6 North America anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S. anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 8 U.S. anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 9 U.S. anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 10 U.S. anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 12 Canada anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 13 Canada anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 14 Canada anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 16 Mexico anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 17 Mexico anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 18 Mexico anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe anti-venom market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 21 Europe anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 22 Europe anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 23 Europe anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 25 Germany anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 26 Germany anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 27 Germany anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 29 UK anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 30 UK anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 31 UK anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 33 France anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 34 France anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 35 France anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 37 Italy anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 38 Italy anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 39 Italy anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 41 Spain anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 42 Spain anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 43 Spain anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Denmark anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 45 Denmark anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 46 Denmark anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 47 Denmark anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Sweden anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 49 Sweden anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 50 Sweden anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 51 Sweden anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Norway anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 53 Norway anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 54 Norway anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 55 Norway anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific anti-venom market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 61 China anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 62 China anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 63 China anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 64 China anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 66 Japan anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 67 Japan anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 68 Japan anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 70 India anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 71 India anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 72 India anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 73 South Korea anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 74 South Korea anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 75 South Korea anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 76 South Korea anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Australia anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 78 Australia anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 79 Australia anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 80 Australia anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Thailand anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 82 Thailand anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 83 Thailand anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 84 Thailand anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 86 Latin America anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 87 Latin America anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 88 Latin America anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 89 Brazil anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 90 Brazil anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 91 Brazil anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 92 Brazil anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 93 Argentina anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 94 Argentina anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 95 Argentina anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 96 Argentina anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 97 MEA anti-venom market, by region, 2018 - 2030 (USD Million)
  • Table 98 MEA anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 99 MEA anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 100 MEA anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 101 MEA anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 102 South Africa anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 103 South Africa anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 104 South Africa anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 105 South Africa anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 110 UAE anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 111 UAE anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 112 UAE anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 113 UAE anti-venom market, by end use, 2018 - 2030 (USD Million)
  • Table 114 Kuwait anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 115 Kuwait anti-venom market, by type, 2018 - 2030 (USD Million)
  • Table 116 Kuwait anti-venom market, by mode of action, 2018 - 2030 (USD Million)
  • Table 117 Kuwait anti-venom market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Anti-venom market: market outlook
  • Fig. 14 Anti-venom competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Anti-venom market driver impact
  • Fig. 20 Anti-venom market restraint impact
  • Fig. 21 Anti-venom market strategic initiatives analysis
  • Fig. 22 Anti-venom market: Species movement analysis
  • Fig. 23 Anti-venom market: Species outlook and key takeaways
  • Fig. 24 Snakes market estimates and forecast, 2018 - 2030
  • Fig. 25 Common Cobra market estimates and forecast, 2018 - 2030
  • Fig. 26 Common Krait market estimates and forecast, 2018 - 2030
  • Fig. 27 Russell Viper market estimates and forecast, 2018 - 2030
  • Fig. 28 Others market estimates and forecast, 2018 - 2030
  • Fig. 29 Scorpion market estimates and forecast, 2018 - 2030
  • Fig. 30 Spider market estimates and forecast, 2018 - 2030
  • Fig. 31 Other species market estimates and forecast, 2018 - 2030
  • Fig. 32 Anti-venom Market: Type movement analysis
  • Fig. 33 Anti-venom market: Type outlook and key takeaways
  • Fig. 34 Polyvalent market estimates and forecasts, 2018 - 2030
  • Fig. 35 Monovalent market estimates and forecasts, 2018 - 2030
  • Fig. 36 Anti-venom market: Mode of action movement analysis
  • Fig. 37 Anti-venom market: Mode of action outlook and key takeaways
  • Fig. 38 Cytotoxic market estimates and forecast, 2018 - 2030
  • Fig. 39 Neurotoxic market estimates and forecast, 2018 - 2030
  • Fig. 40 Haemotoxic market estimates and forecast, 2018 - 2030
  • Fig. 41 Cardiotoxic market estimates and forecast, 2018 - 2030
  • Fig. 42 Myotoxic market estimates and forecast, 2018 - 2030
  • Fig. 43 Others market estimates and forecast, 2018 - 2030
  • Fig. 44 Anti-venom market: End use movement analysis
  • Fig. 45 Anti-venom market: End use outlook and key takeaways
  • Fig. 46 Hospitals market estimates and forecasts,2018 - 2030
  • Fig. 47 Clinics market estimates and forecasts,2018 - 2030
  • Fig. 48 Ambulatory surgical centers market estimates and forecasts,2018 - 2030
  • Fig. 49 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 50 Clinical Laboratories market estimates and forecasts,2018 - 2030
  • Fig. 51 Others market estimates and forecasts, 2018 - 2030
  • Fig. 52 Global Anti-venom market: Regional movement analysis
  • Fig. 53 Global Anti-venom market: Regional outlook and key takeaways
  • Fig. 54 Global Anti-venom market share and leading players
  • Fig. 55 North America market share and leading players
  • Fig. 56 Europe market share and leading players
  • Fig. 57 Asia Pacific market share and leading players
  • Fig. 58 Latin America market share and leading players
  • Fig. 59 Middle East & Africa market share and leading players
  • Fig. 60 North America, by country
  • Fig. 61 North America
  • Fig. 62 North America market estimates and forecasts, 2018 - 2030
  • Fig. 63 U.S. key country dynamics
  • Fig. 64 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 65 Canada key country dynamics
  • Fig. 66 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 67 Mexico key country dynamics
  • Fig. 68 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 69 Europe
  • Fig. 70 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 71 UK key country dynamics
  • Fig. 72 UK market estimates and forecasts, 2018 - 2030
  • Fig. 73 Germany key country dynamics
  • Fig. 74 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 75 France key country dynamics
  • Fig. 76 France market estimates and forecasts, 2018 - 2030
  • Fig. 77 Italy key country dynamics
  • Fig. 78 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 79 Spain key country dynamics
  • Fig. 80 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 81 Denmark key country dynamics
  • Fig. 82 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 83 Sweden key country dynamics
  • Fig. 84 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 85 Norway key country dynamics
  • Fig. 86 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 87 Asia Pacific
  • Fig. 88 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 89 China key country dynamics
  • Fig. 90 China market estimates and forecasts, 2018 - 2030
  • Fig. 91 Japan key country dynamics
  • Fig. 92 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 93 India key country dynamics
  • Fig. 94 India market estimates and forecasts, 2018 - 2030
  • Fig. 95 Australia key country dynamics
  • Fig. 96 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 97 South Korea key country dynamics
  • Fig. 98 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 99 Thailand key country dynamics
  • Fig. 100 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 101 Latin America
  • Fig. 102 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 103 Brazil key country dynamics
  • Fig. 104 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 105 Argentina key country dynamics
  • Fig. 106 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 107 Middle East and Africa
  • Fig. 108 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 109 South Africa key country dynamics
  • Fig. 110 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 111 Saudi Arabia key country dynamics
  • Fig. 112 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 113 UAE key country dynamics
  • Fig. 114 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 115 Kuwait key country dynamics
  • Fig. 116 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 117 Market share of key market players - Anti-venom market
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!